Mean fold change of CDH2 expression in the EpCAM-dependent enrichment was 0.28 (range: 0–1.42) in HD, 0.07 (range: 0–1.41) in CDH2 negative HNSCC patients and 2.29 (range: 2.25–2.33) in CDH2 positive HNSCC patients. This evidence concerns the gene CDH2 and head and neck squamous cell carcinoma.